Skip to main content

Hit enter to search or ESC to close

Solutions
Software
Services
Customers
Resources
Company
Contact Us
Login

search

English 日本語简体中文

Solutions
Software
Services
Resources
Company
Contact
Login

search

Solutions
Software
Services
Resources
Company
Contact
Login

Home / Press Coverage / Accelerating the Progress of Kinase Inhibitors in Oncology

Accelerating the Progress of Kinase Inhibitors in Oncology

Accelerating the Progress of Kinase Inhibitors in Oncology

May 20, 2024

Share Share Share

The potential of PBPK modeling in answering key questions around these drugs.

Hannah Jones, PhD
Masoud Jamei, PhD

Recommended for you

Accelerating Oncology Drug FDA Submission with Project Management Services

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer

Newsletter sign up

Why sign up? Because transforming drug development is not just our goal—it’s our obsession. If it’s yours too, then be the first to know of new insights and join us in pushing the boundaries of science.

Quick links

Our Story
Investors
Careers
Locations
News
Services
Software
Resources

Solutions

Regulatory
Non-Animal Navigator™
Discovery
Preclinical
Early clinical
Late clinical
Market access and commercial
Strategic Leadership

Contact

Sales inquiry
Technical support hub

© 2025 Certara. All Rights Reserved. | Privacy policy

x-twitter
facebook
linkedin
youtube